GSK acquires 35Pharma for $950M to expand blood pressure drug portfolio

ArchivedVerified|2 articles|2 sources|1 blocks

Detected: Updated: Analyzed:

Healthcare

NarrativeRadar Analysis·Reviewed by M. Reyes·AI-assisted, editorially supervised

Reported Facts

Observable data points shared across all narratives

•GSK agreed to pay $950 million in cash to acquire 35Pharma.
•35Pharma is a Canadian pharmaceutical company.
•The acquisition focuses on a drug targeting high blood pressure.
•The deal was announced on February 25, 2026.

What Could Happen If...

▸GSK successfully integrates 35Pharma's drug into its portfolio GSK could increase its market share in cardiovascular treatments and boost revenue from hypertension drugs.

Market Exposure

StocksGSK sharesUncertain

The $950 million acquisition could affect GSK's stock price depending on investor views on the deal's success and future drug sales.

This is not investment advice. Market exposure is based on conditional event analysis.

Key Actors

Countries

🌍Canada

Organizations

🏛35Pharma 🏛GlaxoSmithKline

Source Coverage

FINANCE

2 articles

More coverage on this story

More on Canada
More on 35Pharma
More on GlaxoSmithKline

Signals

Single-block coverage

Primary Sources (2)

FINANCEBloomberg - MarketsGSK Secures High Blood Pressure Drug in $950 Million Deal FINANCESeeking Alpha - Market NewsGSK to acquire Canada's 35Pharma for $950M in cash

GlaxoSmithKline (GSK) agreed to buy Canadian company 35Pharma for $950 million in cash to gain access to a new high blood pressure medication. This acquisition aims to strengthen GSK's position in the cardiovascular drug market and could impact treatment options for patients with hypertension. The deal reflects ongoing pharmaceutical industry efforts to expand drug pipelines through acquisitions.